A 12-year study of measles-containing vaccines has found no new safety concerns regarding adverse events associated with the measles-mumps-rubella-varicella (MMRV) vaccine compared with the separate measles-mumps-rubella (MMR) and varicella (MMR + V) vaccine. The results of this research have been published in the journal Pediatrics.
Nine outcomes were investigated using information on children ages 12–23 months in the Vaccine Safety Datalink database from 2000–2012, including seven main outcomes (anaphylaxis, ITP, ataxia, arthritis, meningitis/encephalitis, acute disseminated encephalomyelitis, and Kawasaki disease), seizure, and fever. A total of 123,200 MMRV and 584,987 MMR + V doses were analyzed.
No significant differences were observed between the risks for the seven main outcomes when comparing MMRV with MMR + V and several outcomes had few or zero postvaccination events. Both vaccines were associated with fever and febrile seizures seven to 10 days following vaccination among 1-year-old children; MMRV was associated with an increased risk of seizure and fever 7–10 days after vaccination compared with MMR + V, although the risk is less than one febrile seizure per 1,000 injections. Previous research has not identified an increased risk for fever or febrile seizures after administration of either vaccine among 4- to 6-year-old children.
For more information visit KP.org.